The Effect of Ethinyloestradiol and Levonorgestrel on the CYP2C19-mediated Metabolism of Omeprazole in Healthy Female Subjects

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2003 Aug 5

PMID 12895199

Citations 17

Authors

Sanna Palovaara

Gunnel Tybring

Kari Laine

Affiliations

Soon will be listed here.

Abstract

Aims: To study the effect of an oral contraceptive (OC) formulation containing ethinyloestradiol and levonorgestrel (LNG) (combination OC) or LNG alone on the CYP2C19-mediated hydroxylation of omeprazole in healthy females.

Methods: This was an open crossover study with three phases. In phase one, 10 healthy females received a single 40-mg dose of omeprazole. Thereafter the subjects received in a random order either 40 micro g ethinyloestradiol and 75 micro g LNG or 60 micro g LNG alone once daily for 10 days. On day 10, 1 h after the last OC dose, subjects received a single 40-mg oral dose of omeprazole. The plasma concentrations of omeprazole, 5'-hydroxyomeprazole and omeprazole sulphone were determined for up to 8 h.

Results: The use of combination OC increased the area under the curve (AUC) of omeprazole by 38% [95% confidence interval (CI) - 3.8, 80; P = 0.040] and caused a 48% increase (95% CI 28, 68) in the AUC ratio of omeprazole/5-hydroxyomeprazole. LNG alone did not effect the 5'-hydroxylation of omeprazole. Neither of the OC preparations seemed to have an inhibitory effect on the formation of omeprazole sulphone by CYP3A4.

Conclusions: Oral contraceptives containing ethinyloestradiol but not those containing only LNG decrease CYP2C19 activity.

Citing Articles

Proton pump inhibitors use is associated with a higher prevalence of kidney stones: NHANES 2007-2018.

Zhang Y, Liu M, Zhu Z, Chen H BMC Public Health. 2024; 24(1):1215.

PMID: 38698372 PMC: 11067170. DOI: 10.1186/s12889-024-18710-8.

Association between low body weight and cytochrome P-450 enzyme activity in patients with anorexia nervosa.

Sandvik P, Lydersen S, Hegstad S, Spigset O Pharmacol Res Perspect. 2020; 8(3):e00615.

PMID: 32529756 PMC: 7290083. DOI: 10.1002/prp2.615.

Sex Differences in Human and Animal Toxicology.

Gochfeld M Toxicol Pathol. 2016; 45(1):172-189.

PMID: 27895264 PMC: 5371029. DOI: 10.1177/0192623316677327.

Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update.

Wedemeyer R, Blume H Drug Saf. 2014; 37(4):201-11.

PMID: 24550106 PMC: 3975086. DOI: 10.1007/s40264-014-0144-0.

Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring.

Deligiannidis K, Byatt N, Freeman M J Clin Psychopharmacol. 2014; 34(2):244-55.

PMID: 24525634 PMC: 4105343. DOI: 10.1097/JCP.0000000000000087.

References

Abernethy D, Todd E . Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. Eur J Clin Pharmacol. 1985; 28(4):425-8. DOI: 10.1007/BF00544361. View

Stoehr G, Kroboth P, Juhl R, Wender D, Phillips J, Smith R . Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics. Clin Pharmacol Ther. 1984; 36(5):683-90. DOI: 10.1038/clpt.1984.240. View

Jurima M, Inaba T, KALOW W . Mephenytoin hydroxylase activity in human liver: inhibition by steroids. Drug Metab Dispos. 1985; 13(6):746-9. View

Kim M, Bertino Jr J, Gaedigk A, Zhang Y, Sellers E, Nafziger A . Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker. Clin Pharmacol Ther. 2002; 72(2):192-9. DOI: 10.1067/mcp.2002.126174. View

Belle D, Callaghan J, Gorski J, Maya J, Mousa O, Wrighton S . The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity. Br J Clin Pharmacol. 2002; 53(1):67-74. PMC: 1874548. DOI: 10.1046/j.0306-5251.2001.01521.x. View

Hagg S, Spigset O, Dahlqvist R . Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol. 2001; 51(2):169-73. PMC: 2014435. DOI: 10.1111/j.1365-2125.2001.01328.x. View

Gorski J, Wang Z, Wrighton S, Hall S . The effect of hormone replacement therapy on CYP3A activity. Clin Pharmacol Ther. 2000; 68(4):412-7. DOI: 10.1067/mcp.2000.110560. View

Palovaara S, Kivisto K, Tapanainen P, Manninen P, Neuvonen P, Laine K . Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1'-hydroxylation. Br J Clin Pharmacol. 2000; 50(4):333-7. PMC: 2015005. DOI: 10.1046/j.1365-2125.2000.00271.x. View

Laine K, Tybring G, Bertilsson L . No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects. Clin Pharmacol Ther. 2000; 68(2):151-9. DOI: 10.1067/mcp.2000.108949. View

10.

Barnas C, Slimko J, Jones M, Schwartz J . Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans. J Clin Pharmacol. 2000; 40(3):219-30. DOI: 10.1177/00912700022008883. View

11.

Laine K, Palovaara S, Tapanainen P, Manninen P . Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy. Clin Pharmacol Ther. 1999; 66(6):602-8. DOI: 10.1053/cp.1999.v66.103404001. View

12.

Andersson T, Miners J, Veronese M, Birkett D . Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br J Clin Pharmacol. 1994; 37(6):597-604. PMC: 1364821. DOI: 10.1111/j.1365-2125.1994.tb04310.x. View

13.

de Morais S, Wilkinson G, Blaisdell J, Nakamura K, Meyer U, Goldstein J . The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994; 269(22):15419-22. View

14.

Andersson T, Regardh C, Lou Y, Zhang Y, Dahl M, Bertilsson L . Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics. 1992; 2(1):25-31. DOI: 10.1097/00008571-199202000-00005. View

15.

Guengerich F . Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem Res Toxicol. 1990; 3(4):363-71. DOI: 10.1021/tx00016a015. View

16.

Back D, Houlgrave R, Tjia J, Ward S, Orme M . Effect of the progestogens, gestodene, 3-keto desogestrel, levonorgestrel, norethisterone and norgestimate on the oxidation of ethinyloestradiol and other substrates by human liver microsomes. J Steroid Biochem Mol Biol. 1991; 38(2):219-25. DOI: 10.1016/0960-0760(91)90129-s. View

17.

Guengerich F . Metabolism of 17 alpha-ethynylestradiol in humans. Life Sci. 1990; 47(22):1981-8. DOI: 10.1016/0024-3205(90)90431-p. View

18.

Andersson T, Regardh C, Bertilsson L . Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit. 1990; 12(4):415-6. DOI: 10.1097/00007691-199007000-00020. View

19.

Scavone J, Greenblatt D, Locniskar A, Shader R . Alprazolam pharmacokinetics in women on low-dose oral contraceptives. J Clin Pharmacol. 1988; 28(5):454-7. DOI: 10.1002/j.1552-4604.1988.tb05759.x. View

20.

de Morais S, Wilkinson G, Blaisdell J, Meyer U, Nakamura K, Goldstein J . Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994; 46(4):594-8. View